Hansa Biopharma to host conference call to provide interim results for January-September 2022 and Business Update

Published: Sep. 30, 2022 at 5:13 AM CDT

LUND, Sweden, Sept. 30, 2022 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA) will publish its interim report for January-September 2022 at 8:00 CET on October 20, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Presentations" and will also be made available online after the call. Link to presentation

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 020 3936 2999

United States: +1 646 664 1960

Participant access code: 178360

The webcast will be available on https://streams.eventcdn.net/hansa/interim-report-for-january-september-2022/

Updated financial calendar and events 2022/2023

Oct 12, 2022                    H.C. Wainwright KOL Expert call in anti-GBM disease (virtual)

Oct 20, 2022                   Interim Report for January-September 2022

Oct 20, 2022                    Redeye After Work presentation, Gothenburg

Oct 21, 2022                    Redeye Lunch presentation, Stockholm

Oct 26, 2022                    Økonomisk Ugebrev Life Science Conference, Copenhagen

Oct 27, 2022                    HCA Capital Expert call on the commercial progress and launch strategy (virtual)

Nov 22, 2022                    Bryan Garnier KOL Expert call in kidney transplantation (virtual)

Nov 23, 2022                    SEB Healthcare Seminar 2022, Stockholm

Nov 24, 2022                    Redeye Life Science Day, Stockholm

Dec 1, 2022                      Erik Penser Banks Temadag - Health Care, Stockholm

Dec 7, 2022                      Nordic American Life Science Conference in NYC

Dec 15, 2022                    DNB Nordic Healthcare Conference, Oslo

Jan 9, 2023                       JPM Week, San Francisco

Mar 14, 2023                    Carnegie Nordic Healthcare Seminar 2023, Stockholm

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

https://mb.cision.com/Main/1219/3640225/1632923.pdf

20220929 HNSA - PR Conf call invite Q3 2022 ENG FINAL

View original content:

SOURCE Hansa Biopharma AB

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.